Mainstay Medical has received authorization from the Medicines and Healthcare Products Regulatory Agency and the Central Ethics Committee to expand the clinical trial of ReActiv8 to include clinical trial sites in the United Kingdom.
ReActiv8 is an implantable neurostimulation device that is intended to treat people with chronic low back pain.
The new trial sites are starting to enroll subjects. The clinical trial of ReActiv8 started in March 2014, and the original trial sites in Australia and Belgium continue to enroll subjects.
More Articles on Devices:
35 spine, orthopedic devices receive FDA 510(k) clearance in June
DJO Global Net Sales Up 6.5% in 2Q
Aurora Spine Announces 1st U.S. Surgery Using ZIP Graft Bone Dowel